Question 1

What is LL-37?

Accepted Answer

LL-37 is the only human cathelicidin-derived peptide, a 37-amino acid amphipathic alpha-helical sequence cleaved from the hCAP18 precursor protein. It is synthesized for use in controlled laboratory research.

Question 2

What research areas involve LL-37?

Accepted Answer

LL-37 is investigated in preclinical models examining innate immune signaling, antimicrobial activity, membrane disruption mechanisms, and host defense peptide research.

Question 3

How is LL-37 characterized in laboratory settings?

Accepted Answer

Researchers characterize LL-37 by its 37-residue amphipathic alpha-helical structure, cationic charge distribution, and consistent membrane-interaction behavior across model lipid bilayers. Its defined sequence enables reproducible activity in controlled preclinical studies.

Question 4

What makes LL-37 relevant to current research?

Accepted Answer

LL-37 is the sole human cathelicidin and exhibits both direct membrane-disruption activity and indirect signaling effects on innate immune pathways. This dual profile makes it a frequently studied reference peptide in host defense and antimicrobial mechanism research.

Question 5

How is product quality verified?

Accepted Answer

Every batch undergoes 7 rounds of independent analytical testing including HPLC purity analysis, mass spectrometry identity confirmation, endotoxin screening, and sterility verification. Full Certificates of Analysis documenting all results are available for each production lot.

SKU	IP-LL37-5
Intended Use	For laboratory research use only. Not for human consumption.